Spherix Global Insights

September 09, 2022

All Eyes on High-Dose Eylea as Roche’s New Vabysmo Makes Moderate Impact in Blockbuster Eye Disease Market

Roche’s Vabysmo is making inroads into the wet AMD eye disease market, but Regeneron’s behemoth Eylea is holding its own, and a new, higher dose version may further entrench Eylea.

That’s according to the latest survey of 110 ophthalmologists from healthcare research consultants at Spherix. While ophthalmologists initially thought most Vabysmo uptake to be at the expense of Eylea alone, it seems just as much of the new brand’s share is taken from Roche’s cancer drug Avastin, which is used off-label in wet AMD, as well other treatment options.